Ascendis Pharma A/S ASND
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +17.83%
- 1 year
- +23.35%
- Open
- 253.50
- Prev close
- 253.00
- Mkt cap
- 16.53B
- Vol
- 386.70K
- Avg vol
- 704.98K
- EPS
- 13.05
- P/E
- 19.25
- Div yield
- 0.00%
More statistics
- Low
- 249.55
- High
- 255.61
- Forward P/E
- 25.06
- Beta
- 0.00
- Short ratio
- 3.27
- Inst. own
- 102.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 242.38
- 200-d avg
- 237.93
- 1y target
- 304.02
5D chart
Events in this range
- Oct 26, 2026Rating: Citigroup · Buy → Buy
Signals (133)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 4 days ago |
| RSI: Oversold | Oct 27, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
News
-
5 days ago benzinga.com
Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism
Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with…
5 days ago globenewswire.com
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney…
-
2 weeks ago benzinga.com
Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
2 weeks ago benzinga.com
Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market…
1 month ago benzinga.com
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market…
1 month ago benzinga.com
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
1 month ago benzinga.com
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
1 month ago benzinga.com
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
-
1 month ago benzinga.com
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287
Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
-
1 month ago benzinga.com
Ascendis Pharma Authorizes Up To $400M Share Repurchase Program
Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase…
-
1 month ago benzinga.com
Ascendis Pharma Regains Exclusive Rights To TransCon Tech Products After Ending Novo Nordisk Collaboration; Ascendis To Initiate Multiple Programs In Metabolic And Cardiovascular Diseases, Including Obesity
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple…
-
1 month ago benzinga.com
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market…
1 month ago benzinga.com
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Ascendis Pharma released positive 52-week data for TransCon CNP in infants with achondroplasia from its Phase 2 reACHin trial.
-
1 month ago benzinga.com
Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort,…
-
1 month ago benzinga.com
Reported Earlier, Ascendis Pharma To Present New Infant Achondroplasia Trial Data At ESPE 2026
Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for…
-
1 month ago benzinga.com
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
2 months ago benzinga.com
Oil Jumps Near $90 On Iran Risk, California Utilities Crater: Stock Market Today
Brent climbed after new U.S.-Iran strikes, pushing the 10-year yield to a 19-month high; Edison and PG&E collapsed on a wildfire bill.
-
2 months ago benzinga.com
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
-
2 months ago benzinga.com
Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.
-
2 months ago benzinga.com
Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
-
2 months ago benzinga.com
Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.64% to 53,219.55 while the NASDAQ dipped 0.40% to 26,296.20.…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $344
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $345 to $344.
2 months ago benzinga.com
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc.…
2 months ago benzinga.com
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.
-
2 months ago benzinga.com
Ascendis, Biomarin Enter Binding Global Settlement And License Agreement Resolving All Litigation, Granting Ascendis Worldwide Rights To Develop, Commercialize Navepegritide Products, With Royalty Payments On YUVIWEL Sales Through 2030
Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. ("BioMarin") related to the…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Ascendis Pharma, Maintains $345 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $345 price target.
2 months ago benzinga.com
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.
-
2 months ago benzinga.com
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market…
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
2 months ago benzinga.com
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call
Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
-
2 months ago benzinga.com
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of…
2 months ago benzinga.com
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market…
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.
-
4 months ago benzinga.com
Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell Midcap
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index,…
-
4 months ago benzinga.com
Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism
Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint89% of patients completed the three-and-a-half-year trial
4 months ago benzinga.com
Why Is Ascendis Pharma Stock Gaining Friday?
Ascendis Pharma (ASND) stock rises after releasing impressive 5-year Phase 2 data for its hypoparathyroidism drug.
-
4 months ago benzinga.com
Ascendis Pharma A/S Data From Phase 2 PaTH Forward Study Of TransCon PTH Demonstrates Sustained Efficacy, Safety In Participants With Hypoparathyroidism
Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated…
-
5 months ago benzinga.com
Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355
Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.
-
5 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.
-
5 months ago benzinga.com
Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $345
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $342 to $345.
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $326
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $330 to $326.
-
5 months ago benzinga.com
Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of…
-
6 months ago benzinga.com
Ascendis Pharma Commences Trading Of Its Ordinary Shares On Nasdaq, Replacing Listing Of ADSs
Ascendis Pharma A/S (NASDAQ:ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares…